Plain-English translation of NCT07083154 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This 76-week study is testing whether , a new injectable medication, can help improve memory and thinking abilities in people who have both type 2 diabetes and early signs of dementia or memory problems. Half of the participants will receive weekly injections of this medication, while the other half will receive placebo injections, and both groups will continue their regular diabetes medications. The study will measure whether the medication can slow or improve cognitive decline and also examine its effects on brain structure and blood sugar control.
People with type 2 diabetes have a higher risk of developing memory problems and dementia. This study is being done because researchers believe this medication might help protect the brain and slow memory loss in this group, while also helping to control blood sugar.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic about every 4–8 weeks over 18 months for checkups, blood tests, and memory assessments. You will give yourself a weekly injection at home (starting at 2 mg and gradually increasing to 4 mg, with possible increase to 6 mg depending on how well you tolerate it). At weeks 28, 52, and 76, you will have more detailed brain imaging scans and comprehensive memory testing. If your blood sugar remains too high despite the medication, your doctor may add another diabetes medication to help control it.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
China